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Diabetes is associated with b cell failure. But it
remains unclear whether the latter results from
reduced b cell number or function. FoxO1 integrates
b cell proliferation with adaptive b cell function. We
interrogated the contribution of these two processes
to b cell dysfunction, using mice lacking FoxO1 in
b cells. FoxO1 ablation caused hyperglycemia with
reduced b cell mass following physiologic stress,
such as multiparity and aging. Surprisingly, lineage-
tracing experiments demonstrated that loss of
b cell mass was due to b cell dedifferentiation, not
death. Dedifferentiated b cells reverted to progen-
itor-like cells expressing Neurogenin3, Oct4, Nanog,
and L-Myc. A subset of FoxO1-deficientb cells adop-
ted the a cell fate, resulting in hyperglucagonemia.
Strikingly, we identify the same sequence of events
as a feature of different models of murine diabetes.
We propose that dedifferentiation trumps endocrine
cell death in the natural history of b cell failure and
suggest that treatment of b cell dysfunction should
restore differentiation, rather than promoting b cell
replication.INTRODUCTION
The pathogenesis of b cell dysfunction in type 2 diabetes
remains controversial (Talchai et al., 2009). b cells of diabetics
respond poorly to a glucose challenge and fail to mount an
appropriately timed response (Ferrannini, 2010). In addition,
physiologic adaptation of b cell function to conditions like
pregnancy or aging—mainly achieved by modulating b cell
replication—is most taxing for prediabetic individuals, indicating
that not only is the endocrine islet’s homeostatic function poor,
but so is its ability to cope with metabolic or environmental
stressors (Accili et al., 2010).CDuring the course of diabetes, and in animal models of b cell
dysfunction, deficits in adaptive b cell mass are largely viewed
as arising from an unbalanced rate of self-renewal versus
apoptosis (Butler et al., 2007; Rieck et al., 2009). However, the
increased rate of apoptosis in diabetic islets is modest relative
to the impairment of b cell function (Butler et al., 2007), while indi-
vidual variations in b cell mass are extensive (Rahier et al., 2008).
In addition to cell-autonomous defects that can be demon-
strated long before disease onset (Weyer et al., 1999), there
are cell-nonautonomous contributors to b cell dysfunction:
hyperglycemia, dyslipidemia, hormones, cytokines, changes in
endothelial cell function, and vascular flow (Ferrannini, 2010).
The failure of sustainable b cell function under metabolic
stress (e.g., during pregnancy or aging) (Rankin and Kushner,
2010; Rieck et al., 2009) has been attributed to different biolog-
ical mechanisms. Autophagy, a physiologic process of organelle
maintenance, can morph into a disease process under condi-
tions of nutrient oversupply—as seen in diabetes (Hur et al.,
2010). Activation of the unfolded protein response affects insulin
secretion, with subsequent changes in b cell mass (Matsuda
et al., 2010). The limited glycolytic capacity of the b cell can result
in the generation of reactive oxygen species, and the ensuing
oxidative stress can uncouple glucose sensing from insulin
secretion (Robertson, 2004).
In addition to processes impinging on b cell survival and hence
on islet mass, b cell dedifferentiation can be observed in vitro
(Weinberg et al., 2007) and during ex vivo culture of human islets
(Gershengorn et al., 2004). Evidence that it might occur in
common forms of b cell failure has been inferred from partial
pancreatectomy studies (Jonas et al., 1999), but has not been
shown to occur in type 2 diabetes, nor has its mechanism
been explored.
Recent studies have shone light on fate conversion of pancre-
atic cells under genetically extreme conditions, such as: (1) a cell
to b cell in response to forced expression of Pax4 (Collombat
et al., 2007) or extreme ablation of b cells (Thorel et al., 2010);
(2) b cell to duct epithelium in response to Akt gain of function
(Elghazi et al., 2009); (3) b cell to a cell in response to ablation
of the DNA methyltransferase Dnmt1 in b cells (Dhawan et al.,
2011; Papizan et al., 2011); and (4) exocrine-to-endocrine cellsell 150, 1223–1234, September 14, 2012 ª2012 Elsevier Inc. 1223
in response to overexpression of transcription factors, Pdx1,
MafA, and Neurog3 (Zhou et al., 2008).
Transcription factor FoxO1 integrates signals regulating b cell
mass (Kitamura et al., 2002; Okamoto et al., 2006) and stress
response (Kawamori et al., 2006; Kitamura et al., 2005; Martinez
et al., 2006). FoxO1 has been found to determine cell fate in
differentiating adipocytes (Nakae et al., 2003), myoblasts
(Kitamura et al., 2007), and enteroendocrine cells (Talchai
et al., 2012). But considerably less is known about FoxO1
requirements in maintaining cell differentiation. In light of its
role, straddling diverse aspects of b cell physiology, we used
mice lacking FoxO1 in b cells to probe mechanisms of b cell
failure in type 2 diabetes. Surprisingly, our studies reveal that
b cell dedifferentiation and conversion into other endocrine cell
types are underrecognized mechanisms of b cell failure in type
2 diabetes and that FoxO1 is required to enforce the b cell fate
under metabolic stress.
RESULTS
FoxO1 Ablation Increases Susceptibility to Metabolic
Stress
To determine FoxO1 activity during diabetes progression, we
surveyed FoxO1 immunoreactivity in b cells of mice with insulin-
resistant diabetes: GIRKO (Lin et al., 2011), as well as db/db
mice. In addition to euglycemic mice (glucose%150 mg/dl), we
studied mice with mild fasting hyperglycemia (150–250 mg/dl),
and severe hyperglycemia (R500 mg/dl). In euglycemia, FoxO1
showedcytoplasmic localization in b cells (Figure 1A). In contrast,
with mild hyperglycemia, FoxO1 could be found in a distinctive
punctate nuclear pattern in b cells, consistent with its nuclear
translocation in response to oxidative stress (Kitamura et al.,
2005). In this condition, we also saw partial loss of insulin and
FoxO1-expressing cells (Figure 1A). As hyperglycemia increased,
loss of FoxO1 immunoreactivity paralleled loss of insulin content
(Figure 1A), consistent with previous observations (Kitamura
et al., 2005; Lin et al., 2011; Xuan et al., 2010). Nonetheless, we
don’t know whether loss of FoxO1 is a cause or an effect of
b cell failure, nor do we know what happened to the ‘‘missing’’
b cells.
To address these questions, we utilized mice with somatic
deletion of Foxo1 in b cells (IKO) (Kitamura et al., 2009). To
document Foxo1 deletion in Cre-expressing cells, we generated
IKO:Rosa26-Gfp and control Ins2-cre:Foxo1fl/+:Rosa26-Gfp
mice. As expected, Gfp+ cells lacked FoxO1 immunoreactivity
(Figure 1B), while measurements of Foxo1 mRNA in collage-
nase-purified islets demonstrated an 70% decrease com-
pared with wild-type controls, with residual mRNA probably
arising from islet vasculature and connective tissue (Fig-
ure S1A available online). In basal conditions, IKO mice showed
normal body weight (Figure S1B), islet architecture, b cell
morphology by electron microscopy (EM), and levels of
mRNA encoding b cell markers Pdx1, MafA, Nkx6.1, NeuroD1,
Insulin1, Insulin2, Prohormone convertase 1 (Pcsk1), Pcsk2,
Glucokinase (Gck), and Glucose transporter 2 (Glut2). In-
terestingly, they showed increased mRNA encoding Foxo3a
and Foxo4 (Figures S1C–S1H). IKO mice displayed normal
glucose tolerance and insulin and glucagon secretion (Figures1224 Cell 150, 1223–1234, September 14, 2012 ª2012 Elsevier Inc.S1I–S1Q). In addition, fasting blood glucose was normal, as
were fed insulin and glucagon levels and pancreatic content of
insulin and glucagon (Figures 1D–1J).
To assess the consequences of FoxO1 ablation in the b cell
response to physiologic stress, we studied multiparous females
(Rieck et al., 2009) and aging males (Rankin and Kushner, 2010)
as pathophysiologic models of b cell stress. In both models, we
saw an 30% decrease of b cell mass and an 50% increase in
a cell mass, associated with fasting hyperglycemia, decreased
fed insulin levels and pancreatic insulin content, and increased
fed glucagon levels and pancreatic glucagon content (Figures
1C–1J). We further examined b cell and a cell function in vivo,
and found that both multiparous and aging IKO mice had
impaired glucose tolerance, decreased insulin secretion, and
elevated glucagon secretion in response to glucose and argi-
nine compared to wild-type controls (Figures S1I–S1P). To
distinguish between an intrinsic defect of insulin and glucagon
secretion in multiparous IKO mice and secondary changes
brought about by glucose toxicity (Robertson, 2004), we iso-
lated islets and compared insulin secretion. We observed
reduced insulin release in response to different glucose con-
centrations in islets from IKO multiparae (Figures S1Q and
S1R), consistent with a cell-autonomous effect of the Foxo1
mutation.
We confirmed these findings in two additional models of
b cell dysfunction: (1) hyperglycemia–induced by chemical abla-
tion of b cells with low-dose streptozotocin (STZ) (Movassat
et al., 1997), and (2) insulin resistance–caused by insulin
receptor haploinsufficiency (InsR+/) (Kido et al., 2000). In
both instances, we saw decreased b cell mass, altered pancre-
atic glucagon and insulin content, abnormal fed plasma insulin
and glucagon, with fasting hyperglycemia (Figures S1S–S1Y).
The constellation of hyperglycemia, hyperglucagonemia and
relative hypoinsulinemia with decreased insulin-to-glucagon
ratios is reminiscent of human type 2 diabetes (Dunning and
Gerich, 2007).
Cell-Autonomous Dedifferentiation of FoxO1-Deficient
b Cells
To examine whether b cell dysfunction was due to loss of
b cell number or b cell function, we employed lineage tracing
to mark cells in which Ins2-cre had been active. In these
experiments, we used a sensitive approach based on auto-
mated localization of confocal immunofluorescence, and
compared virgin female and multiparous IKO mice with
matched wild-type controls using immunohistochemistry with
Gfp and insulin (Figure 2A, green and red, respectively). The
activation frequency of Ins2-cre in b cells—as defined by
the ratio of colocalization area (yellow) to insulin-immunoreac-
tive area (red) —was 75%–88% in virgin IKO and wild-type
mice (Figures 2A, 2B, and S2A). We then assessed the propor-
tion of green (Gfp+), red (Ins+), and yellow cells (Gfp+/Ins+) in
IKO versus wild-type multiparae. The predictions were that
(1) if reduced b cell mass in IKO multiparae was due to
decreased cell-autonomous survival, the number of yellow
cells should decrease; (2) if reduced b cell mass was due to
impaired repopulation of the islets by newly formed b cells
that escaped Cre-mediated recombination, the number of
Figure 1. FoxO1 Localization during Dia-
betes Progression and Foxo1 Knockout
(A) Immunofluorescence with insulin (green), and
FoxO1 (red) in euglycemic (glucose = 100 mg/dl),
mildly hyperglycemic (glucose = 150–250 mg/dl)
db/db mice, and severely hyperglycemic GIRKO
mice (glucose >500 mg/dl) (n = 10). Insets show
representative b cells.
(B) Lineage tracing analysis of recombination at
the Foxo1 locus in IKO:RosaGfp and control mice
(Ins2-Cre:Foxo1fl/+;RosaGfp or Ins2-Cre:Foxo1+/+;
RosaGfp) using Gfp (green, indicates recombina-
tion) and FoxO1 antibodies (red) in pancreata from
3-month-old mice (n = 3).
(C) Islet morphology and immunohistochemistry
with insulin (red) and glucagon (Gcg, green) in
multiparous or aging (16- to 20-month-old) wild-
type and IKO mice (n = 4).
(D) Fasting blood glucose.
(E) b cell mass.
(F) a cell mass.
(G) Fed plasma insulin.
(H) Fed plasma glucagon.
(I) Pancreatic insulin content.
(J) Pancreatic glucagon content (n = 8–16 for
blood metabolite analyses, n = 4 for morphometry
and n = 8 for pancreatic hormone content). Data
represent means ± SEM. *p < 0.05, and **p < 0.01
by Student’s t test.
See also Figure S1.red cells should decrease, and (3) if both mechanisms con-
tributed to the reduction, red and yellow cells should decrease
(Figure 2A).
Instead, we observed similar numbers of red cells in the two
genotypes (Figure S2A), while—to our surprise—multiparousCell 150, 1223–1234, SepIKO mice showed a large increase in the
number of green cells, i.e., recombined
b cells that no longer produced insulin.
There were large inter-islet variations,
even within the same pancreas. In some
islets we observed residual punctate
insulin immunoreactivity, resulting in faint
merged fluorescence (i.e., intensity of red
color%40% of average wild-type b cells)
(Figure 2C, middle panels), while in others
insulin immunoreactivity could no longer
be detected, resulting in completely
green cells (Figure 2C, right-hand panels).
Double immunohistochemistry with Gfp
and Pdx1, or Gfp and MafA revealed
that wholly green cells expressed neither
b cell transcription factor (Figure 2C),
while cells with residual faint yellow
immunoreactivity showed persistent ex-
pression of both proteins (Figure 2D).
Thus, based on the proposed criteria for
the progression of b cell failure (Weir
and Bonner-Weir, 2004), it appears that
faintly yellow cells are partly degranu-lated b cells, while green cells are dedifferentiated b cells (Wein-
berg et al., 2007). The two cell types combined represented
25% of total recombined cells in IKO islets, thus accounting
nearly entirely for the loss of b cell mass in Foxo1-ablated multi-
parae (Figure S2B). To extend our findings, we performedtember 14, 2012 ª2012 Elsevier Inc. 1225
Figure 2. Lineage Tracing of b Cells
in Multiparae
(A) Experimental design and expected outcomes
of lineage-tracing experiments.
(B) Immunofluorescence with Gfp (green) and
insulin (red) in IKO:RosaGfp and control RosaGfp
virgins.
(C) Immunofluorescence with Gfp (green)
and insulin, Pdx1, or MafA antibodies (red) in
IKO:RosaGfp and control RosaGfp multiparae.
Middle and right panels show representative islets
with moderate (middle) and extreme degrees
(right) of loss of insulin immunoreactivity.
(D) Immunofluorescence with Gfp (green) and
insulin, Pdx1, or MafA (red), showing degranulated
(orange) and dedifferentiated (green) b cells in
IKO:RosaGfp multiparae (n = 4 for each group).
(E) Electron microscopy showing a representative
wild-type b cell (left) and a degranulated (orange
arrow, dg) or a dedifferentiated b cell (green arrow,
dd) in IKO multiparae.
(F–I) Immunohistochemistry with Gfp (green) and
C-peptide, Pcsk1-encoding prohormone-con-
vertase1, Pcsk2-encoding prohormone-con-
vertase2, and Glut2 (red) in recombined b cells of
multiparous IKO:RosaGfp and control RosaGfp
mice. In some sections, DNA is counterstained
with DRAQ5 (blue or white). Insets represent indi-
vidual color channels.
See also Figure S2.lineage-tracing studies in aging IKO (>16 months old), and IKO/
InsR+/males, age-matched withmultiparous females (8months
old). We confirmed the occurrence of degranulation and dedif-
ferentiation in both models (Figure S2A). These data suggest
that dedifferentiation is a shared cell-autonomous mechanism
of b cell loss, rather than a specific response to multiple
pregnancies.
The presence of similar numbers of b cells that escaped
recombination in IKO and controls (Figure S2B, red bars) demon-
strates that the two groups did not differ by their regenerative
abilities, i.e., that the difference in b cell mass is due to cell-
autonomous effects of Foxo1 ablation.1226 Cell 150, 1223–1234, September 14, 2012 ª2012 Elsevier Inc.The data are consistent with the
explanation that FoxO1-deficient b cells
have normal survival, but become
dedifferentiated. Accordingly, islet EM
showed cells with scattered residual
EM-dense granules, typical of degra-
nulated b cells, as well as cells with
empty granules in multiparous IKO
mice (Figure 2E). In addition, double
immunostaining with Gfp and various
b cell markers demonstrated a near-
complete loss of C-peptide, Pcsk1, and
Pcsk2 (encoding prohormone conver-
tases 1 and 2) and substantial decreases
of Glut2 and Gck immunoreactivities
in multiparous and in aging IKO mice
(Figures 2F–2I and S2D). Further, mRNAs
encoding Pdx1, Nkx6.1, NeuroD1, MafA,Pcsk2, Gck, and Glut2 were decreased in islets isolated
from IKO multiparae (Figure S2C), providing a potential expla-
nation for the secretory defects observed in vivo (Figures 1
and S1).
FoxO1 Ablation Does Not Alter b Cell Death or Self-
Renewal In Vivo
Apoptosis contributes to b cell loss (Butler et al., 2007). In light of
the possible proapoptotic role of FoxO1, we surveyed apoptotic
cells by quantification of cleaved caspase-3 and by TUNEL
assays, but found similar numbers in multiparous IKO and
wild-type mice (Figures 3A and 3B). Interestingly, no pancreatic
Figure 3. Analysis of b Cell Survival in FoxO1-Deficient Mice
(A) TUNELassay or active-caspase3 (green) in insulin-, somatostatin-, Pp-, and
glucagon-immunoreactive cells (red) of multiparous wild-type and IKO mice.
Chormone colocalized with apoptotic nuclei, suggesting that
apoptosis occurred in dedifferentiated cells.
To quantitate the contribution of dedifferentiation versus
death to b cell loss, we compared the ratios of Gfp and insulin
immunoreactive areas to total pancreatic area in virgin and
multiparous mice from both genotypes. In basal conditions,
we observed no difference between virgin animals of the two
genotypes, indicating that they possess the same complement
of b cells and similar recombination rates. If the reduced b cell
mass in multiparous IKO was due to cell death, we should
have observed a reduction of both Gfp- and insulin-immunore-
active areas as a fraction of total pancreatic area in IKO versus
wild-typemice. But we observed that only the insulin-immunore-
active area was reduced in multiparous IKOmice, while the Gfp-
immunoreactive area was similar between the two genotypes
(Figure 3C). These data show that loss of b cell mass in IKOmul-
tiparae is due to loss of insulin production in b cells, not to cell
death.
We also investigated the possibility that FoxO1-ablated b cells
had abnormal turnover. But immunohistochemistry with the cell
cycle antigen Ki67 under basal conditions, or during and after
pregnancy showed no difference in labeling between the two
genotypes. We obtained similar data in glucagon-producing
cells (Figures S3A–S3C), ruling out a contribution of altered
cell replication to decreased b cell mass and increased a cell
mass.FoxO1-Deficient b Cells Revert to an Uncommitted
Endocrine Progenitor-like Stage
We probed the differentiation stage of FoxO1-deficient, insulin-
depleted b cells, using markers of pre-endocrine progenitors
(Sox9), endocrine progenitors (Neurog3), and committed endo-
crine cells (ChromograninA, ChgA) (Seymour et al., 2007).
FoxO1-deficient Gfp+ cells were Sox9/ChgA+, indicating that
they are endocrine pre-b cells, and not pre-endocrine progen-
itors (Figure 4A). Neurog3 detection in adult islets is prob-
lematic at best (Wang et al., 2009). Accordingly, Neurog3
immunoreactivity was hardly detectable in islets from virgin
3-month-old mice of either genotype (Figure S4A), but clearly
visible in fetal pancreas (Figure S4B). We detected a stark
increase of Neurog3 immunoreactivity in FoxO1-ablated cells
of multiparous, aging, and InsR+//IKO mice (Figures 4A and
S4D). Double immunohistochemistry demonstrated that cells
expressing high levels of Neurog3 (Neurog3high) contained no
insulin, Pdx1, and MafA while mature b cells showed the
opposite pattern (Figures 4B and S4E) (Wang et al., 2009).
These findings were corroborated by increases in Neurog3
mRNA and protein levels in islets from IKO mice (Figures 4C
and S4C).(B) Quantification of apoptotic nuclei as detected by TUNEL assays in wild-
type and IKO mice (n = 8).
(C) Quantification of Gfp (green) or insulin immunoreactive area (red). The
pixel area was converted to mm2 and plotted as percentage of total pancreas
area (also expressed in mm2) from virgins and multiparae (n = 4 for each
group).
Data show means ± SEM. *p < 0.05 by Student’s t test. See also Figure S3.
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Figure 4. Staging of Differentiation of
FoxO1-Deficient b Cells
(A) Immunofluorescence with Gfp (green, indi-
cating recombined b cells) and insulin (red, left
panels), or ChgA (red, central panels), Neurog3
(red, central right panels), Sox9 (red, right
panels) in multiparous IKO:RosaGfp and con-
trol RosaGfp mice. DNA is counterstained with
DAPI.
(B) Immunofluorescence with insulin (white), and
Neurog3 (red, left panels), Pdx1 or MafA (green),
and Neurog3 (red, central and right panels) in
multiparous IKO and wild-type mice.
(C) Neurog3 immunoblotting in the indicated
tissues.
See also Figure S4.Multipotency of Dedifferentiated b Cells
To investigate the cause of b cell dedifferentiation, we studied
plasticity and pluripotentcy of FoxO1-deleted cells. In human
embryonic stem cells, FOXOs regulate pluripotency via OCT4,
NANOG, and SOX2 (Zhang et al., 2011), and in human fetal1228 Cell 150, 1223–1234, September 14, 2012 ª2012 Elsevier Inc.pancreas, OCT4 is coexpressed with
NEUROG3 and NESTIN (Wang et al.,
2009). In addition, pluripotent bone mar-
row stromal cells coexpressing OCT4,
NANOG, and NEUROG3 can be differen-
tiated into insulin+ cells (Zhao et al.,
2008). Interestingly, during embryonic
development and postnatal maintenance
of b cells, L-Myc is temporally coregu-
lated with Neurog3+ progenitors and their
descendants (White et al., 2008). L-Myc is
required to induce cellular reprogram-
ming (Nakagawa et al., 2010). Accord-
ingly, we found that Gfp-immunoreactive
b cells from wild-type mice express low
levels of Oct4 and L-Myc, and little if
any Nanog, while lineage-traced IKO
b cells expressed high levels of all three
proteins (Figure 5A), as did human
embryonic stem cells and mouse embry-
onic pancreas (Figures S5A and S5B).
Sox2 was not detectable in islets from
either genotype, consistent with the
finding that Foxo1 deletion did not affect
b cell proliferation (Figure 5A) (Basu-Roy
et al., 2012). Furthermore, in IKO islets
from multiparae, we detected cells coex-
pressing Neurog3high and L-Myc. L-Myc
andOct4 were hardly detectable in b cells
from wild-type mice, but highly enriched
in insulin-depleted IKO islets (Figures
S5B and S5C). These results are sup-
ported by the findings that mRNA
encoding Oct4, Nanog, and L-Myc are
expressed at comparable levels in isletsfrom IKO multiparae and flow-sorted Neurog3-Gfp+ cells iso-
lated at E14.5, although they are both considerably lower than
embryonic stem cells (Figure S5D). The findings indicate that
‘‘empty’’ b cells in IKO mice are not degranulated b cells, but
represent a distinctive pre-b cell differentiation stage.
Figure 5. Multipotency and Plasticity of
Dedifferentiated b Cells
(A) Immunofluorescence with Gfp (green, indi-
cating recombined b cells) and Oct4 (red, left
panels), or L-Myc (red, central panels), Nanog (red,
central right panels), Sox2 (red, right panels) in
multiparous IKO:RosaGfp and control RosaGfp
mice.
(B) Immunofluorescence with Gfp (green) (re-
combined cells) and a cocktail of glucagon
(labeling a cells), pancreatic polypeptide (Pp cells),
and somatostatin (d cells) antibodies (red) in
multiparous and aging IKO:RosaGfp and control
RosaGfp mice. Orange arrows indicate merged
fluorescence (M); red arrows indicate pre-existing
a, d, and Pp cells. Insets illustrate representative
cells. In the central right panel, the yellow area
shows automatic localization assigned by soft-
ware analysis of confocal images. Boxed regions
(non-b cells) are shown at higher magnification on
top. The far right panel demonstrates a represen-
tative z stack of confocal images showing coloc-
alization of merged fluorescence to the same cell.
(C) Immunohistochemistry with Gfp (green, indi-
cating recombined b cells), and Pdx1, or MafA
(magenta) and glucagon (Gcg, red) in IKO and
wild-type multiparae.
(D) Immunohistochemistry with glucagon (red) and
nestin or vimentin (blue) in IKO and wild-type
multiparae, including representative z stacks of
confocal images (n = 4–6 in all panels).
See also Figure S5.Conversion of Dedifferentiated b Cells into Other
Hormone-Producing Cells
We further hypothesized that the multipotency of Ins/Neuro-
g3high/Oct4+/L-Myc+ cells in IKO islets increased their plasticity.
Given the rise in a cell mass and pancreatic glucagon content in
multiparous and in aging IKO mice, we asked whether b cell
dedifferentiation was associated with conversion into other
endocrine pancreatic cell types. To this end, we used lineage
tracing to follow the fates of dedifferentiated b cells by confocal
immunofluorescence colocalization of Gfp with islet hormones
other than insulin (Figure 5B, green and red, respectively). If
insulin-depleted b cells converted into other islet cell types, we
expected to detect FoxO1-ablated b cells (green) that became
immunoreactive with glucagon, somatostatin, or pancreatic
polypeptide (Pp) and thus gave rise to yellow immunoreactivityCell 150, 1223–1234, Sep(Figures 5B and S5E). For simplicity, we
refer to yellow cells as a, d, and Pp
cells. Indeed, we observed a population
of Gfp-labeled cells decorated by anti-
bodies to pancreatic hormone other than
insulin; this population accounted for
an 35% increase in a, d, and Pp cell
mass in IKO mice (Figures 5B, S5E, and
S5F). Following the fate of lineage-traced
b cells, we detected Gfp+/glucagon+
cells that were immunoreactive with
Pdx1 or MafA in IKO multiparae (Fig-ure 5C). This result demonstrates that some dedifferentiated
b cells gave rise to glucagon-containing cells. These data
indicate that there is conversion of former b cells into a, d, and
Pp cells.
Importantly, none of the converted cells coexpressed insulin,
supporting the view that regression to a pre-b cell (possibly Neu-
rog3+) state is a prerequisite for conversion into non-b cells.
Indeed, lineage tracing showed that recombined FoxO1-
deficient cells from multiparous and from aging mice have
increased expression of MafB (Figure S5F), a factor involved in
the determination of prehormone producing (uncommitted) as
well as glucagon-producing cells (Hang and Stein, 2011). This
result provides an explanation for the hyperglucagonemia and
increased pancreatic glucagon content seen in IKO multiparae
(Figures 1F, 1H, and 1J).tember 14, 2012 ª2012 Elsevier Inc. 1229
Plasticity of Converted a and d Cells in IKO Mice
We further analyzed the similarities between glucagon-immuno-
reactive cells in IKO mice and bona fide a cells. We detected
increased transcript levels encoding glucagon and MafB, but
not a cell markers Arx, Pax6, and Brn4 in IKO islets compared
to controls (Figure S5G). Consistent with the lineage tracing
data, we found ectopic expression of b cell transcription factors
Pdx1, MafA, and Nkx6.1 in converted a and d cells (Figures S5I–
S5K). These data provide further support for b cell conversion
into non-b, hormone-producing cells. Similarly, marker analysis
of insulin-expressing cells in IKO multiparae identified not only
reduced numbers of Pdx1+, MafA+, and Nkx6.1+ cells, but also
Pdx1+, MafA+, or Nkx6.1+ cells that failed to express insulin
(Figures S5I–S5K). The latter cell type might represent a cells
converting into b cells (Thorel et al., 2010). But it’s unlikely, given
that we observed reduced b cells, expanded a, d, and Pp cells,
and increased pancreatic glucagon content, and we did not
detect insulin/glucagon double-positive cells.
In addition, we did not find colocalization of FoxO1 with a, d,
and Pp cells, thus ruling out a cell non-autonomous role of
ectopically expressed FoxO1 (Figures S5L and S5M). The
mRNA analysis of a cell markers, and the ectopic expression
of b cell transcription factors in a, and d cells indicate that
conversion into glucagon- or somatostatin-producing cells was
due to increased plasticity rather than transdifferentiation. These
data indicate that lack of FoxO1 in b cells curtails insulin expres-
sion, and renders key b cell transcription factors, Nkx6.1, Pdx1,
MafA, and Neurog3 (Zhou et al., 2008), insufficient to maintain
b cell identity.
b cells, islets, and pancreas can dedifferentiate and activate
expression of mesenchymal markers, such as vimentin and
nestin, in vitro (Russ et al., 2011; Zulewski et al., 2001), but this
phenomenon has not been described in vivo. Using immunohis-
tochemistry with nestin or vimentin, we investigated whether
conversion from b- to a cells required coexpression of mesen-
chymal markers in vivo. We observed occasional colocalization
of the two proteins with glucagon in IKO multiparae, but not in
wild-type controls (Figure 5D). The data suggest that expression
of mesenchymal markers influences conversion to a cells.
Relevance of the Findings to Type 2 Diabetes
Is dedifferentiation of b cells a unique finding in Foxo1 knock-
outs, or is it a common path to b cell failure? Using insulin-
resistant diabetic GIRKO (Lin et al., 2011) and db/db mice, we
measured b cell differentiation using ChgA, FoxO1, and insulin
immunoreactivity. In moderately diabetic mice, insulin+/ChgA+
cells decreased by 15%–45%, whereas in severely diabetic
mice 90%–95% of islet cells were ChgA+ but only 10%–
15% were insulin+ or hormone+ (Figures 1A and 6A). Abundant
ChgA+/hormone cells persisted in severely hyperglycemic
mice (Figures 6A, 6B, and S6A), providing a practical illustration
of ‘‘empty b cells’’ during diabetes progression. These cells were
also decorated by endocrine marker Synaptophysin, and
showed progressive loss of FoxO1 during diabetes develop-
ment (Figures S6B–S6D), leading to a large increase of Synapto-
physin+/ FoxO1 cells in severely diabetic mice. These data
provide evidence that a large proportion of endocrine mass is re-
tained despite severe hyperglycemia (500 mg/dl), and that1230 Cell 150, 1223–1234, September 14, 2012 ª2012 Elsevier Inc.FoxO1 is required to enforce b cell identity in insulin-resistant
diabetes.
Similar to mice with FoxO1 ablation, diabetes in GIRKO and
db/dbmice was associated with a marked increase in Neurog3,
Oct4, and L-Myc immunoreactivities that mirrored loss of insulin
and b cell markers, MafA and Pdx1 (Figures 6C and S6E–S6G). In
addition, we confirmed the increased plasticity of islets in db/db
mice, as we detected glucagon-containing cells that reacted
with MafA, vimentin, or nestin (Figure 6D).
These data indicate that genetic ablation of FoxO1 pheno-
copies the molecular abnormalities associated with diabetes
progression, and support the conclusions that b cell dedifferen-
tiation is pathogenic in the b cell dysfunction of type 2 diabetes
and that the gradual loss of FoxO1 expression during diabetes
progression causes b cell dysfunction (Figure 7).
DISCUSSION
The main conclusions of this work are (1) b cell dedifferentiation
occurs commonly in type 2 diabetes and is associated with an
acquired loss of FoxO1 function; (2) there exists an inverse rela-
tionship between FoxO1 and b cell differentiation as diabetes
unfolds, with a striking increase of Neurog3, Oct4, Nanog, and
L-Myc expression; (3) FoxO1 is required to maintain b cell iden-
tity and prevent b cell conversion into non-b pancreatic endo-
crine cells in response to chronic pathophysiologic stress.
Dedifferentiation as a Mechanism of b Cell Loss
Our study provides direct in vivo evidence that b cell dedifferen-
tiation with loss of FoxO1 is a shared mechanism of b cell failure
in diverse models of metabolic stress. This discovery represents
a departure from the view that b cell failure is caused by a reduc-
tion of b cell mass secondary to apoptosis (Butler et al., 2007).
While the metabolic abnormalities in mice with b cell-specific
FoxO1 knockout are not as marked as those seen in the other
diabetic models, this might be due to compensatory increases
in other FoxOs (Figure S1G). Nevertheless, the impairment of
b cell mass and function caused by lack of FoxO1 is consistently
observed in other models of diabetes (Kobayashi et al., 2012).
We provide surprising evidence for the reemergence of endo-
crine progenitor-like cells during adulthood as a result of b cell
dysfunction.We find degranulated b cells, with decreased insulin
content and preserved expression of b cell markers, Pdx1 and
MafA. Although this state had been postulated based on mRNA
measurements (Jonas et al., 1999), our data provide anatomical,
ultramorphological, and functional evidence for these cells.
The ‘‘Selfish’’ b Cell
The identification of a set of dedifferentiated b cells (ChgA+/Neu-
rog3high/L-Myc+/Oct4+) that no longer contribute to insulin
production in diabetic islets supports the view that a progressive
decline of b cell function, or ‘‘b cell exhaustion’’ antedates the
physical demise of b cells (Ferrannini, 2010). Importantly, we
show that b cell dedifferentation is a regression to an endocrine
progenitor-like stage rather than a degenerative stage.We spec-
ulate that there is an advantage to b cells in adopting the dedif-
ferentiated fate, and suggest that this ‘‘selfish’’ behavior facili-
tates their survival.
Figure 6. b Cell Dedifferentiation in
Diabetes—GIRKO Mice
(A) Immunohistochemistry with insulin (green),
combined glucagon (gcg), pancreatic polypeptide
(Pp), somatostatin (Sms) (blue), and ChgA (red).
(B) Quantification of area of ChgA-immunoreactive
area (red), 4-hormone-immunoreactive area (in-
sulin, glucagon, Pp, somatostatin) (yellow), and
their ratios (gray). The pixel area was converted to
mm2 and plotted as percentage of total pancreatic
area (also expressed in mm2) (n = 5 for each
group). Data show means ± SEM. *p < 0.05 by
Student’s t test.
(C) Immunohistochemistry with insulin (white) and
Neurogenin3, L-Myc, or Oct4 (red).
(D) Immunohistochemistry with glucagon (white)
and MafA (red) (top panels); or glucagon (green)
and vimentin (red) (middle panels); or glucagon
(green) and nestin (red) (bottom panels) (n = 4 for
each group).
See also Figure S6.We propose that during metabolic stress, FoxO1 is required to
restrict the b cell fate by promoting genes required for b cell iden-
tity and by preventing reactivation of embryonic endocrine
progenitor genes. Our work expands the implications of the
increased plasticity of pancreatic endocrine cells observed as
a survival mechanism inmodels of extreme b cell ablation (Thorel
et al., 2010), by suggesting that plasticity occurs in common
forms of b cell dysfunction, and is caused by the downregulation
of FoxO1 that follows hyperglycemia-induced oxidative stress
(Kitamura et al., 2005). The loosening of b cell fate observedCell 150, 1223–1234, Sepfollowing loss of FoxO1 is consistent
with the phenotype of Akt gain of function
(Elghazi et al., 2009). But because Akt has
multiple substrates in addition to FoxO1,
Akt gain-of-function results in an even
greater diversity of cellular fates, while
the effect of FoxO1 ablation is limited to
endocrine lineages.
Similarly, reactivation of Neurog3 has
been seen in the context of extreme
depletion of exocrine tissue (Xu et al.,
2008), or b cells (Thorel et al., 2010). In
normal pancreatic endocrine differentia-
tion, Neurog3 inhibits its own expression
(Wang et al., 2008). In adult islets, in-
creased Neurog3 levels can decrease
b cell survival (Dror et al., 2007). The rise
of Neurog3 in FoxO1-deficient b cells
is consistent with a repressor role of
FoxO1 in the regulation of Neurog3 ex-
pression in gut and pancreatic endocrine
differentiation (Al-Masri et al., 2010;
Talchai et al., 2012). These data uncover
a role of FoxO1 to inhibit Neurog3 reacti-
vation during diabetes development, and
illustrate that Neurog3 overexpression is
associated with b cells dysfunction.The model arising from our observations can help explain why
decreases in b cell mass occur slowly as a function of diabetes
duration (Rahier et al., 2008). It is consistent with and provides
an explanation for the slow progression and temporary revers-
ibility of b cell dysfunction, vindicating the concept of ‘‘b cell
rest’’ as a diabetes treatment (Weng et al., 2008).
Conversion of Different Cell Types in Diabetic Islets
Genetic loss of FoxO1 by conditional knockout phenocopies
key aspects of the natural history of islet dysfunction in diabetictember 14, 2012 ª2012 Elsevier Inc. 1231
Figure 7. Proposed Mechanism of b Cell Failure
Healthy b cells produce insulin and have cytoplasmic FoxO1 (yellow). In the
early phases of metabolic stress, insulin production (green) is maintained, but
FoxO1 undergoes nuclear translocation to enforce the b cell fate (red). If the
stress persists, FoxO1 expression declines (blue nucleus) as Neurog3, Oct4,
Nanog, and L-Myc are reactivated, and b cell transcription factors are unable
to forestall a drop in insulin production (gray). The outcome is twofold: most
former b cells revert to an uncommitted endocrine progenitor stage (gray). A
subset of cells undergoes conversion into other hormone-producing cells
(orange).mice. First, canonical b cell transcription factors, Pdx1, MafA,
and Nkx6.1 are insufficient to maintain b cell fate in an altered
metabolic environment. Second, our lineage-tracing studies
show that a subset of dedifferentiated b cells undergoes
conversion into other endocrine cell types, providing a potential
explanation for the reciprocal relationship between b cells and
a cells in diabetes. While quantitatively small when compared
to the total number of dedifferentiated b cells, converted b cells
account for the relative increase in a cells, and thus provide
a potential explanation for the baffling alterations in insulin-
to-glucagon ratios and hyperglucagonemia observed in human
type 2 diabetes (Dunning and Gerich, 2007). Third, we provide
in vivo evidence for the longstanding in vitro and ex vivo
observations of activation of mesenchymal markers in endo-
crine cells during metabolic stress (Russ et al., 2011; Zulewski
et al., 2001).Conclusions
Our findings indicate that there is an ample time window
between functional depletion of insulin in b cells, and their
demise. These observations offer a glimmer of hope that
salvaging dedifferentiated b cells might provide an approach to
treating b cell dysfunction in diabetes. This idea is supported
by the observations that a fraction of dedifferentiated b cells
can produce other types of pancreatic hormones, indicating
that they can become hormone-producing cells, and providing
impetus to develop approaches to redifferentiate them into func-
tional b cells. Our work highlights a FoxO1-dependent mecha-
nism that prevents dedifferentiation and provides insight into
maintenance of b cell function in type 2 diabetes.1232 Cell 150, 1223–1234, September 14, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Antibodies, Western Blotting, and Immunohistochemistry
We fixed and processed tissues for immunohistochemistry as described
(Kitamura et al., 2009). We applied perfused fixation (Padilla et al., 2010),
and antigen retrieval for nuclear transcription factor detection (Nacalai USA).
A list of antibodies used in these studies is provided in Extended Experimental
Procedures. We used FITC-, Cy3-, and Alexa-conjugated donkey secondary
antibodies (Jackson Immunoresearch Laboratories and Molecular Probes),
or peroxidase staining as described (Kitamura et al., 2009). Nuclear extracts
for western blotting were prepared from 50–100 islets from four to six mice
from each condition (Wang et al., 2009). Ten micrograms of proteins was
loaded into each well. We used Apoptag In Situ apoptosis detection kit for
TUNEL assays (Millipore) and stained nuclei with DAPI or DRAQ5 (Cell
Signaling). Image acquisition, analysis, and b cell mass morphometry have
been described (Xuan et al., 2010). For electron microscopy, a cell mass
morphometry and immunofluorescent colocalization analysis were performed
as described (Gao et al., 2007). Coexpression of Gfp and insulin or glucagon,
somatostatin, and Pp cells, was verified and quantified as ratio of overlapping
area/total immunoreactive area (single-stained regions – overlapping area) as
automatically assigned by confocal microscopy and Laser Scanning Micro-
scope Software (Zeiss LSM 510 and 710). Four pancreatic sections from
four mice from each genotype were sampled 150 mm apart, and used for
a two-tailed paired Student’s t test analysis. Total pancreas area was
captured at 1003, and immunostaining area at 2003. The ratio of immunore-
active area/pancreas area was converted from pixel to mm2 and plotted
as mm2.
Mice
Ins2-cre (Herrera, 2000), Rosa26-eGfp (Gu et al., 2002), InsR+/– (Accili et al.,
1996), and Foxo1flox/lox mice have been described (Paik et al., 2007). We
performed genotyping as described (Kitamura et al., 2009). The Columbia
University Animal Care and Utilization Committee has approved all studies.
Metabolic Studies
We injected STZ i.p. at a dose of 50 mg/kg for five consecutive days in 3- to
4-month-old male mice and began to analyze them 21 days later (Movassat
et al., 1997). We analyzed multiparous females (defined as having carried
at least three pregnancies to term) at 8 months of age, and age-matched
virgin control females. We analyzed IKO:InsR+/– mice and controls at
8 months of age. For aging studies, we analyzed 16- to 20-month-old
male mice. We performed glucose tolerance tests in overnight-fasted mice
by intraperitoneal injection of glucose (2 g/kg) (Xuan et al., 2010). We per-
formed GSIS and arginine-stimulated insulin secretion tests as described
(Kido et al., 2000). We measured glucagon by radioimmunoassay and insulin
by ELISA (Millipore).
RNA Procedures
We used standard techniques for mRNA isolation and quantitative PCR.
References to PCR primer sequences are provided in the Extended
Experimental Procedures.
Statistical Analyses
We used two-tailed Student’s t test for data analysis. *p < 0.05; **p < 0.01 by
Student’s t test. We present data as means ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2012.07.029.
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